Epinephrine · Epinephrine 0.15 Pediatrics, Epinephrine 0.3 Adults

What is Epinephrine?

Epinephrine is a non-selective alpha and beta-adrenergic receptor agonist that increases cardiac contractility and heart rate while causing peripheral vasoconstriction. It is also studied in asthma and bronchospasm.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Epinephrine 0.15 Pediatrics, Epinephrine 0.3 Adults, Neffy, Adrenaline

Drug type

Small molecule

Targets

alpha-adrenergic receptor (ADRA1A), beta-adrenergic receptor (ADRB1)

Mechanism

Agonist of alpha-adrenergic receptor (ADRA1A) and beta-adrenergic receptor (ADRB1)

Pathways

cardiac contractility, heart rate, peripheral vasoconstriction

Therapy area

Immunology, Respiratory

Developer

Sterling

In trials of

AMPH, SPRY

FDA status

Approved as Epinephrine 0.15 Pediatrics, Epinephrine 0.3 Adults, Neffy (August 11, 1969), NDA016803 · FDA label

✅ FDA-approved uses

• Emergency treatment of type I allergic reactions, including anaphylaxis (Neffy)

From the indications section of the FDA label (version of Apr 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic ReactionsAsthmaBronchospasmShortness of BreathUpper Respiratory Tract InfectionWheezing

Other drugs acting on ADRA1A / ADRB1

Sources

• FDA label (DailyMed)
• FDA label Epinephrine (2026-06-08), indications
• FDA label Neffy (2026-04-24), indications
• FDA label Epinephrine 0.15 Pediatrics (2026-01-12), indications
• FDA label Epinephrine 0.3 Adults (2026-01-12), indications
• ClinicalTrials.gov NCT01188577
• ClinicalTrials.gov NCT01255709
• ClinicalTrials.gov NCT01255709
• ClinicalTrials.gov NCT01255709

Updated Oct 3, 2026.